{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:32:36Z","timestamp":1768530756254,"version":"3.49.0"},"reference-count":22,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background:<\/jats:title>\n<jats:p>Hypopigmented mycosis fungoides is a rare variant of mycosis fungoides that may mimic many benign inflammatory hypopigmented dermatoses, and as yet there is no identified marker to differentiate between them.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Aim:<\/jats:title>\n<jats:p>The aim of this study was to study the expression of thymocyte selection\u2013associated high-mobility group box (TOX) in hypopigmented mycosis fungoides and one of its inflammatory mimickers (early active vitiligo) to assess its potential as a differentiating diagnostic marker.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Methods:<\/jats:title>\n<jats:p>A case\u2013control study was done using immunohistochemical analysis of TOX expression in 15 patients with hypopigmented mycosis fungoides and 15 patients with early active vitiligo. Immunohistochemical analysis was done via a semi-quantitative method and an image analysis method.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Results:<\/jats:title>\n<jats:p>Hypopigmented mycosis fungoides showed a statistically significant higher expression of TOX than early active vitiligo. The expression of TOX was positive in a majority of hypopigmented mycosis fungoides cases (14 cases, 93.3%), while only one case (6.7%) of vitiligo was weakly positive. TOX also displayed 93.3% sensitivity and specificity, with a cut-off value of 1.5.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st5\">\n<jats:title>Limitations:<\/jats:title>\n<jats:p>This was a pilot study testing hypopigmented mycosis fungoides against only a single benign inflammatory mimicker (early vitiligo). Other benign mimickers were not included.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st6\">\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Our findings showed that TOX expression can differentiate hypopigmented mycosis fungoides from early active vitiligo which is one of its benign inflammatory mimickers, with a high degree of sensitivity and specificity.<\/jats:p>\n<\/jats:sec>","DOI":"10.4103\/ijdvl.ijdvl_1011_18","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T11:29:21Z","timestamp":1576582161000},"page":"819-825","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thymocyte selection\u2013associated high-mobility group box as a potential diagnostic marker differentiating hypopigmented mycosis fungoides from early vitiligo: A pilot study"],"prefix":"10.25259","volume":"87","author":[{"given":"Mona Abdel-Halim","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa Yassin","family":"Soltan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-1","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.adengl.2017.02.010","article-title":"Clinicopathologic variants of mycosis fungoides","volume":"108","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5144\/0256-4947.2012.283","article-title":"Profile of mycosis fungoides in 43 Saudi patients","volume":"32","author":"AlGhamdi","year":"2012","journal-title":"Ann Saudi Med"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/DAD.0000000000000379","article-title":"Frequency of hypopigmented mycosis fungoides in Egyptian patients presenting with hypopigmented lesions of the trunk","volume":"37","author":"Abdel-Halim","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ni767","article-title":"TOX: An HMG box protein implicated in the regulation of thymocyte selection","volume":"3","author":"Wilkinson","year":"2002","journal-title":"Nat Immunol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.coi.2011.12.001","article-title":"The many roles of TOX in the immune system","volume":"24","author":"Aliahmad","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-7","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1182\/blood-2014-05-571778","article-title":"Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma","volume":"125","author":"Huang","year":"2015","journal-title":"Blood"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/jdv.13651","article-title":"TOX expression and role in CTCL","volume":"30","author":"McGirt","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00403-014-1501-7","article-title":"TOX expression in different subtypes of cutaneous lymphoma","volume":"306","author":"Morimura","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/archderm.135.4.407","article-title":"Association of the K\u00f6bner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris","volume":"135","author":"Njoo","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-11","first-page":"17","article-title":"Vitiligo vs. hypopigmented mycosis fungoides (histopathological and immunohistochemical study, univariate analysis)","volume":"16","author":"El-Darouti","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/29.4.6166661","article-title":"Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures","volume":"29","author":"Hsu","year":"1981","journal-title":"J Histochem Cytochem"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-15","doi-asserted-by":"publisher","first-page":"e0117479","DOI":"10.1371\/journal.pone.0117479","article-title":"TOX acts an oncological role in mycosis fungoides","volume":"10","author":"Yu","year":"2015","journal-title":"PLoS One"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1365-2133.1973.tb15444.x","article-title":"Can mycosis fungoides begin in the epidermis? A hypothesis","volume":"88","author":"Ryan","year":"1973","journal-title":"Br J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-17","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1590\/abd1806-4841.20132336","article-title":"Hypopigmented mycosis fungoides: A review of its clinical features and pathophysiology","volume":"88","author":"Furlan","year":"2013","journal-title":"An Bras Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4103\/2229-5178.120662","article-title":"Inflammatory vitiligo versus hypopigmented mycosis fungoides in a 58-year-old Indian female","volume":"4","author":"Soro","year":"2013","journal-title":"Indian Dermatol Online J"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/jid.2013.461","article-title":"MiR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides\/cutaneous T-cell lymphoma","volume":"134","author":"McGirt","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-20","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1111\/ijd.13080","article-title":"Two cases of CD8-positive hypopigmented mycosis fungoides without TOX expression","volume":"55","author":"Ichimura","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/01.EWX.0000525982.47129.30","article-title":"TOX as a diagnostic and prognostic marker for mycosis fungoides","volume":"15","author":"El-Hamd Neinaa","year":"2018","journal-title":"J Egypt Womens Dermatol Soc"},{"key":"10.4103\/ijdvl.IJDVL_1011_18\/ref-22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjd.14508","article-title":"TOX expression in cutaneous T-cell lymphomas: An adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype","volume":"175","author":"Schrader","year":"2016","journal-title":"Br J Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/thymocyte-selection-associated-high-mobility-group-box-as-a-potential-diagnostic-marker-differentiating-hypopigmented-mycosis-fungoides-from-early-vitiligo-a-pilot-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/thymocyte-selection-associated-high-mobility-group-box-as-a-potential-diagnostic-marker-differentiating-hypopigmented-mycosis-fungoides-from-early-vitiligo-a-pilot-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T09:43:09Z","timestamp":1634982189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/thymocyte-selection-associated-high-mobility-group-box-as-a-potential-diagnostic-marker-differentiating-hypopigmented-mycosis-fungoides-from-early-vitiligo-a-pilot-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":22,"alternative-id":["10.4103\/ijdvl.IJDVL_1011_18"],"URL":"https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_1011_18","relation":{},"subject":[],"published":{"date-parts":[[2021,2,1]]},"article-number":"819"}}